List of Excipients in Branded Drug DOXYCYCLINE HYCLATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	DOXYCYCLINE HYCLATE	doxycycline hyclate	0591-6100	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	DOXYCYCLINE HYCLATE	doxycycline hyclate	0591-6100	CROSCARMELLOSE SODIUM
Actavis Pharma Inc	DOXYCYCLINE HYCLATE	doxycycline hyclate	0591-6100	FD&C BLUE NO. 1
Actavis Pharma Inc	DOXYCYCLINE HYCLATE	doxycycline hyclate	0591-6100	FD&C YELLOW NO. 6

Generic Drugs Containing DOXYCYCLINE HYCLATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	doxycycline hyclate	0143-2112	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	doxycycline hyclate	0143-2112	CROSCARMELLOSE SODIUM
Hikma Pharmaceuticals USA Inc	doxycycline hyclate	0143-2112	DOCUSATE SODIUM
Hikma Pharmaceuticals USA Inc	doxycycline hyclate	0143-2112	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in DOXYCYCLINE HYCLATE?

# Of NDCs	Excipient
9	ACETIC ACID
58	ALCOHOL
26	AMMONIA
128	ANHYDROUS LACTOSE

Doxycycline Hyclate Excipient Strategy and Commercial Opportunities

Last updated: September 23, 2026

Doxycycline hyclate is a mature tetracycline antibiotic with broad generic competition, limited active-ingredient patent protection, and continuing formulation opportunities. Commercial value is concentrated in modified-release products, low-dose anti-inflammatory products, pediatric and liquid presentations, taste-masked dosage forms, and differentiated delivery systems.

The strongest excipient strategies address five technical problems: gastrointestinal irritation, esophageal injury, bitter taste, moisture and light sensitivity, and control of doxycycline release. Products that improve administration without materially increasing doxycycline exposure have the clearest regulatory path through abbreviated or hybrid applications.

What is the formulation profile of doxycycline hyclate?

Doxycycline hyclate is a hydrochloride hemiet-hydrate salt of doxycycline. It is used in tablets, capsules, delayed-release tablets, oral suspensions, injectable products, and veterinary dosage forms. FDA-approved products use doxycycline hyclate or doxycycline monohydrate, with the labeled strength generally expressed as doxycycline-equivalent content rather than salt weight [1].

Attribute	Formulation implication
Tetracycline antibiotic	Requires protection from chelation with calcium, magnesium, aluminum and iron
Bitter taste	Requires coating, complexation, flavoring or multiparticulate masking in liquids and pediatric products
Gastrointestinal irritation	Supports delayed release, lower peak exposure, food-compatible dosing and gastroprotective design
Esophageal injury risk	Supports rapid dispersion, adequate water volume and reduced tablet lodging
Light and moisture sensitivity	Supports opaque packaging, protective coatings and controlled humidity manufacturing
Dose-dependent antibacterial activity	Favors immediate-release products for infection treatment
Anti-inflammatory activity at sub-antimicrobial doses	Supports low-dose modified-release products such as 40 mg doxycycline regimens

Doxycycline is less affected by food than several older tetracyclines, but polyvalent cations can reduce absorption. Product labeling continues to warn against simultaneous administration with antacids, iron, calcium and magnesium-containing products [2].

Which excipients are used in doxycycline hyclate products?

Commercial products use conventional tablet and capsule excipients, but the selection affects dissolution, stability, patient tolerability and generic substitutability.

Immediate-release tablets

Typical excipient systems include:

• Microcrystalline cellulose as a diluent and compression aid
• Lactose monohydrate or anhydrous lactose as a filler
• Croscarmellose sodium or sodium starch glycolate as a disintegrant
• Povidone as a binder
• Magnesium stearate or stearic acid as a lubricant
• Colloidal silicon dioxide as a glidant
• Film coatings based on hypromellose, polyethylene glycol, titanium dioxide and iron oxides

Acticlate and other immediate-release doxycycline tablets illustrate the commercial use of standard excipients rather than a highly specialized platform [3]. This creates a low-cost manufacturing route but limits differentiation unless the product adds taste masking, dispersibility, reduced pill burden or a novel administration profile.

Capsules

Capsules generally use gelatin or hypromellose shells with powder, pellet or granule fills. The shell can incorporate titanium dioxide, iron oxides and colorants for product identification and light protection. Capsule fills may include lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate and silica.

Capsules offer a practical platform for:

• Multiparticulate delayed release
• Sprinkle administration
• Bead-based taste masking
• Separate immediate-release and delayed-release fractions
• Reduced tablet size at high doxycycline strengths

Delayed-release tablets

Doryx MPC is an example of a delayed-release doxycycline hyclate product based on a modified-release platform. Its commercial differentiation depends on release control and administration performance rather than on the doxycycline molecule itself [4].

Delayed-release strategies may use:

• Enteric polymers such as methacrylic acid copolymers
• Hypromellose phthalate or hypromellose acetate succinate
• Ethylcellulose or other permeability-controlling polymers
• Polyvinylpyrrolidone-based binders
• Protective seal coats
• Controlled-porosity coatings
• Functional film layers that reduce release in the stomach and permit release in the intestine

The key development risk is that a coating designed to reduce gastric exposure can also delay or lower total exposure, especially when the product is taken with food, antacids or mineral supplements.

What excipient strategies can improve doxycycline tolerability?

The highest-value strategies target administration-related adverse events rather than the antibiotic’s pharmacology.

Reducing esophageal exposure

Doxycycline products carry warnings concerning esophagitis and esophageal ulceration, particularly when taken with insufficient water or immediately before lying down [2]. Excipient and dosage-form approaches include:

1. Rapid disintegration after ingestion.
2. Reduced tablet density to limit prolonged esophageal lodging.
3. Smooth, low-friction film coatings.
4. Smaller tablets or capsules.
5. Buffered or rapidly dispersible granules.
6. Delayed release that minimizes dissolution in the esophagus and stomach.

A formulation that claims reduced esophageal injury would require clinical or postmarketing evidence. Dissolution improvement alone is unlikely to establish a meaningful safety advantage.

Improving gastrointestinal tolerability

Options include enteric protection, lower peak concentration, controlled release and food-compatible dosing. A challenge exists: infection treatment generally benefits from prompt systemic exposure, while prolonged release may be more useful for chronic inflammatory indications.

For anti-inflammatory use, a low-dose regimen can reduce antimicrobial selection pressure. Oracea uses a 40 mg modified-release approach for rosacea, with a pharmacologic design intended to provide anti-inflammatory activity without an antibacterial dose [5].

Addressing chelation and food interactions

Excipients cannot eliminate doxycycline chelation by calcium, magnesium, iron or aluminum. A formulation can, however, separate release from co-administered minerals or use a dosage form with improved absorption robustness.

Potential commercial claims include:

• Lower food-effect variability
• Reduced interaction with mineral supplements
• Improved absorption in patients using antacids
• Simplified dosing instructions

These claims would require comparative pharmacokinetic studies and interaction data. They are more commercially defensible when tied to a defined formulation architecture.

What formulations are protected by doxycycline patents?

The basic doxycycline hyclate compound is mature, and commercial protection is concentrated in formulation and method-of-use patents. Relevant categories include:

Protection category	Commercial purpose	Likely regulatory route
Delayed-release tablets	Reduces gastric release and differentiates dosing	505(b)(2) or ANDA, depending on reference
Modified-release capsules	Separates immediate and delayed fractions	505(b)(2) or ANDA
Low-dose anti-inflammatory products	Treats rosacea or periodontal inflammation without conventional antibiotic dosing	505(b)(2), with method-of-use protections
Taste-masked suspensions	Expands pediatric and adherence markets	ANDA or 505(b)(2)
Sprinkle capsules	Supports patients unable to swallow tablets	ANDA or 505(b)(2)
Stable liquid formulations	Addresses reconstitution, shelf life and palatability	505(b)(2) or ANDA
Manufacturing processes	Improves particle size, uniformity, stability or coating performance	Product and process patent claims
Veterinary formulations	Targets companion-animal and livestock administration	Abbreviated or veterinary regulatory pathways

The most valuable claims typically require a specific combination of doxycycline form, polymer system, release profile, dissolution performance and clinical use. Broad claims covering doxycycline with ordinary fillers or lubricants are more vulnerable to obviousness challenges.

When does doxycycline hyclate lose exclusivity?

Doxycycline’s original compound and early product protections expired decades ago. Generic immediate-release doxycycline products are widely available in the United States and international markets. Current exclusivity depends on the individual brand, formulation and indication.

Product or category	Main differentiation	Exclusivity position
Generic immediate-release doxycycline hyclate	Conventional tablet or capsule	Mature generic market
Oracea 40 mg	Modified-release, sub-antimicrobial rosacea treatment	Product-specific formulation and method-of-use protection
Doryx and Doryx MPC	Delayed-release doxycycline tablets	Formulation and product-specific protection
Acticlate	Immediate-release tablet	Limited differentiation from ordinary generics
Liquid and suspension products	Taste, stability and pediatric administration	Potentially differentiated through formulation patents

FDA Orange Book listings identify patents and exclusivity associated with individual reference products. Listings can change through patent expiry, delisting, litigation, pediatric exclusivity and regulatory updates [6]. A product-by-product Orange Book review is required before relying on a specific generic entry date.

How do Paragraph IV challenges affect doxycycline products?

Paragraph IV risk is highest where a branded product depends on formulation patents rather than the active ingredient. An ANDA applicant can challenge listed patents by asserting that the patents are invalid, unenforceable or not infringed.

The main challenge targets are:

• Polymer composition
• Coating thickness
• Dissolution windows
• Particle-size distributions
• Immediate-release and delayed-release ratios
• Low-dose anti-inflammatory methods
• Capsule or tablet architecture
• Food-effect and administration claims

A generic applicant may pursue a “skinny label” that excludes a patented indication. This strategy is most relevant where the product has both an unprotected antibacterial use and a protected inflammatory or dermatologic use. The risk is lower when the patented formulation is difficult to design around but higher when the patent claims only a narrow dissolution profile.

What FDA regulatory pathways apply to new doxycycline formulations?

ANDA pathway

An ANDA is appropriate when the proposed product can demonstrate pharmaceutical equivalence and bioequivalence to a listed reference product. This route is attractive for conventional immediate-release tablets and capsules.

The main development requirements are:

• Same active ingredient and dosage form
• Equivalent strength
• Pharmaceutical equivalence
• Bioequivalence
• Adequate chemistry, manufacturing and controls data
• Labeling consistent with the reference product

505(b)(2) pathway

A 505(b)(2) application is more suitable for a new release profile, new route, new dosage form or new clinical use that relies partly on FDA findings for an approved doxycycline product.

Commercially attractive 505(b)(2) concepts include:

• Pediatric oral suspension
• Long-acting doxycycline
• Low-dose anti-inflammatory products
• Rapidly dispersible products
• Administration through feeding tubes
• Improved taste and reduced dosing frequency

The pathway can support three-year marketing exclusivity for certain new clinical investigations, although patent protection remains product-specific and claim-dependent [7].

What commercial opportunities exist for doxycycline excipient innovation?

Pediatric and geriatric liquid products

Liquid doxycycline products face taste, sedimentation, reconstitution and stability challenges. A commercially useful system would combine:

• Strong taste masking
• Low sedimentation
• Simple reconstitution
• Room-temperature stability
• Minimal interaction with dosing syringes
• Compatibility with common feeding tubes
• Clear separation from mineral-containing co-medications

Doxycycline hyclate’s unpleasant taste makes ion-exchange resins, cyclodextrins, lipid-based barriers and polymer-coated particles potential platforms. The product must preserve rapid and complete release after administration.

Sprinkle and orally dispersible products

Multiparticulate capsules or sachets could target patients with dysphagia and pediatric populations. The main constraints are mouthfeel, dose uniformity, stability and avoidance of prolonged contact with the oral cavity.

Veterinary formulations

Veterinary doxycycline has applications in companion animals, including respiratory, dermatologic and tick-borne infections. Opportunities include flavored tablets, oral pastes, suspension concentrates and dosing systems for small animals. Veterinary products can support premium pricing when they improve compliance and reduce handling complexity.

Long-acting dosage forms

A once-daily or less frequent product could compete with conventional twice-daily treatment in selected indications. The formulation must maintain adequate exposure without increasing gastrointestinal adverse events or producing subtherapeutic concentrations that could promote resistance.

Combination products

Potential combinations include doxycycline with agents for dermatologic inflammation, periodontal disease or localized delivery. Combination products face added patent, stability, interaction and regulatory burdens. Their strongest commercial case is in a defined specialty indication with poor adherence to existing therapy.

How strong is the patent estate for doxycycline hyclate?

The estate is weak for the core molecule and conventional immediate-release products but stronger for narrow, clinically differentiated delivery systems.

Patent factor	Assessment
Core active ingredient	Weak, mature and broadly generic
Conventional tablet excipients	Weak unless linked to unexpected performance
Modified release	Moderate to strong if claims cover a specific architecture and dissolution profile
Low-dose anti-inflammatory use	Moderate, subject to claim scope and remaining terms
Pediatric taste masking	Potentially strong if supported by clinical, sensory and stability data
Manufacturing process	Moderate if process parameters produce non-obvious product attributes
Veterinary delivery	Moderate in specialized dosage forms
Trade secrets	Useful for coating, granulation and flavor systems but not a substitute for blocking patents

A robust program should combine formulation patents with manufacturing know-how, stability data, trademarks, device protection and regulatory exclusivity. Reliance on a single broad excipient claim creates substantial invalidity and design-around risk.

How does doxycycline hyclate compare with doxycycline monohydrate?

Doxycycline hyclate and doxycycline monohydrate are different salt or hydration forms of doxycycline used in approved products. Their commercial distinction is often based on formulation, tolerability and labeling rather than antibacterial activity alone.

Factor	Doxycycline hyclate	Doxycycline monohydrate
Product use	Tablets, capsules, delayed-release products, injections	Tablets, capsules and selected oral products
Formulation focus	Release control, stability and conventional generic supply	Tolerability and alternative salt-form positioning
Commercial differentiation	Stronger in modified-release products	Stronger where gastrointestinal tolerability is emphasized
Generic competition	Extensive	Extensive
Patent opportunity	Formulation, coating and method of use	Salt-form, formulation and tolerability claims

The salt form should be selected with attention to aqueous behavior, solid-state stability, dissolution, manufacturing yield and bioequivalence. A salt-form change alone is unlikely to support durable differentiation without demonstrated product advantages.

What licensing and partnership opportunities exist?

Doxycycline is a suitable platform for licensing where the partner contributes a proprietary excipient system, coating technology, taste-masking platform or specialty distribution channel.

The most attractive deal structures involve:

• Regional rights for pediatric or dermatology products
• Co-development of a 505(b)(2) modified-release product
• Licensing of multiparticulate coating technology
• Contract development and manufacturing for veterinary products
• Acquisition of an abbreviated application with established bioequivalence data
• Specialty commercialization rights for low-dose anti-inflammatory products

Deal valuation should focus on remaining patent term, Orange Book status, development-stage risk, reference-product competition, reimbursement, manufacturing complexity and the ability to avoid listed patents.

What generic launch scenarios exist for doxycycline products?

Immediate-release generic launch

This is the lowest-risk scenario. Competition is usually price-driven, with limited protection from formulation patents. Manufacturing scale, API sourcing and wholesaler access determine commercial performance.

Design-around launch against delayed-release patents

A generic applicant may use a different polymer, coating sequence, particle architecture or dissolution profile. The commercial risk is litigation and possible failure to match the reference product’s pharmacokinetics.

Skinny-label launch

A generic may omit a protected indication while retaining unprotected antibacterial indications. This can permit earlier entry, but the applicant must manage induced-infringement risk and promotional controls.

505(b)(2) differentiated launch

A new liquid, long-acting, pediatric or anti-inflammatory formulation can command higher pricing but requires clinical, regulatory and market-access investment. Success depends on demonstrating a clear benefit over inexpensive generic doxycycline.

Key Takeaways

• Doxycycline hyclate is a mature active ingredient with limited value in conventional immediate-release products.
• The strongest commercial opportunities are modified release, pediatric liquids, taste-masked multiparticulates, sprinkle products and veterinary dosage forms.
• Excipients should address esophageal exposure, gastrointestinal tolerability, taste, moisture, light and release control.
• The strongest patent claims combine specific excipient systems with measurable dissolution, stability or clinical performance.
• Orange Book and Paragraph IV analysis is product-specific because remaining protection generally relates to formulations and methods of use.
• Immediate-release generics face intense price competition; differentiated products may support 505(b)(2) economics.
• A durable strategy should combine patents, manufacturing know-how, regulatory exclusivity, trademarks and channel access.

FAQs

Can doxycycline hyclate be formulated as a liquid suspension?

Yes. The principal challenges are bitter taste, sedimentation, reconstitution stability, dose uniformity and protection from moisture and degradation. A successful product would need validated stability and palatability data.

Which excipients are most useful for doxycycline taste masking?

Ion-exchange resins, polymer coatings, cyclodextrins, lipid barriers and multiparticulate systems are potential options. The preferred system must preserve dissolution and avoid binding doxycycline after administration.

Does an enteric coating improve doxycycline safety?

It can reduce dissolution in the stomach, but it does not by itself prove lower esophageal or gastrointestinal injury. The coating must also preserve bioavailability and provide a consistent release profile.

Is doxycycline hyclate eligible for a new 505(b)(2) product?

A new dosage form, release profile, route, formulation or clinical use may support a 505(b)(2) application if the applicant can rely partly on FDA findings for an approved doxycycline product and supplies the required bridging data.

What is the best commercial niche for a new doxycycline hyclate product?

The most defensible niches are pediatric or dysphagia-friendly products, low-dose anti-inflammatory therapy, taste-masked liquid formulations and veterinary products with clear administration advantages.

References

1. U.S. Food and Drug Administration. (2024). Doxycycline hyclate: Approved drug products and prescribing information.
2. U.S. Food and Drug Administration. (2024). Doxycycline hyclate prescribing information. DailyMed.
3. Avet Pharmaceuticals Inc. (2023). Acticlate: Doxycycline hyclate tablets prescribing information. DailyMed.
4. Mayne Pharma International Pty Ltd. (2023). Doryx MPC: Doxycycline hyclate delayed-release tablets prescribing information. DailyMed.
5. Galderma Laboratories, L.P. (2023). Oracea: Doxycycline capsules prescribing information. DailyMed.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
7. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA Guidance and Regulatory Information.